Tumor Markers – new developments

Dr. Weeks’ Comment:  Questions of prognosis are never answered with certainty as regards cancer and it resolution to either regression or remission.  Nonetheless, cancer tumor markers are useful when considered in the context of a physical examination and a careful patient history. 


Tumor Markers in Metastatic Breast Cancer Subtypes

Frequency of Elevation and Correlation With Outcome

R. Yerushalmi; S. Tyldesley; H. Kennecke; C. Speers; R. Woods; B. Knight; K. A. Gelmon

Posted: 02/08/2012; Annals of Oncology. 2012;23(2):338-345. © 2012 Oxford University

Background: Little is known about the correlations between tumor markers (TMs), breast cancer subtypes, site(s) of metastasis and prognosis.
Methods: Women diagnosed with metastatic breast cancer were included. Breast cancer subtypes were defined as LuminalA, LuminalB, LuminalHer2, Her2, Basal and non-Basal triple negative (TN). Levels of elevation of TM values [cancer antigen 15-3 (CA 15-3), carcinoembryonic antigen (CEA) and cancer antigen 125 (CA 125)] among the subtypes were analyzed. Site(s) of metastasis and outcomes were captured.
Results: Eight hundred and ten patients were included. Luminal subtypes were associated with an elevation in at least one TM: 90.8% of LuminalHer2+, 90% of LuminalB and 88.6% of LuminalA. TMs were less frequently elevated in Basal (74.1%) and non-Basal TN (71.4%) cases (P < 0.001). CA 15-3 was the most frequently elevated TM. The incidence of TM elevation did not differ between patients with solitary versus multiple metastatic sites. Breast cancer-specific survival (BCSS) was significantly worse for patients with elevated TMs (P = 0.001).
Conclusions: TM elevation of CA 15-3, CEA and/or CA 125 was documented in the majority of patients with metastatic breast cancer with CA 15-3 occurring most commonly. Luminal subtypes expressed elevated TMs significantly more frequently compared with the non-Luminal groups. TM elevation was not different between the different sites of metastasis. Overall, elevated TMs predicted a worse BCSS.

Leave a Comment

Your email address will not be published. Required fields are marked *